| Cardiovascular Function and Risk Factors | Lifetime | 396 | ES 4 | 99.27 |
| Cardiovascular Disease and Adiposity | Lifetime | 192 | ES 5 | 98.92 |
| Heart Failure Treatment and Management | Lifetime | 234 | ES 3 | 99.11 |
| Atrial Fibrillation Management and Outcomes | Lifetime | 503 | ES 9 | 98.76 |
| Cardiac pacing and defibrillation studies | Lifetime | 362 | ES 5 | 98.89 |
| Blood Pressure and Hypertension Studies | Lifetime | 539 | ES 6 | 98.45 |
| Lipoproteins and Cardiovascular Health | Lifetime | 428 | ES 6 | 98.21 |
| Acute Myocardial Infarction Research | Lifetime | 563 | ES 19 | 98.32 |
| Cardiac Health and Mental Health | Lifetime | 360 | ES 4 | 97.49 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 577 | ES 29 | 97.66 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 674 | ES 16 | 97.10 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | Lifetime | 209 | ES 3 | 95.17 |
| Pharmaceutical Economics and Policy | Lifetime | 424 | ES 3 | 95.14 |
| Medication Adherence and Compliance | Lifetime | 387 | ES 10 | 94.77 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 993 | ES 22 | 92.57 |
| Healthcare Systems and Technology | Lifetime | 556 | ES 23 | 92.19 |
| Pericarditis and Cardiac Tamponade | Lifetime | 559 | ES 19 | 88.81 |
| Potassium and Related Disorders | Lifetime | 670 | ES 12 | 88.97 |
| Heart rate and cardiovascular health | Lifetime | 463 | ES 5 | 77.24 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 66 | ES 3 | 96.49 |
| Heart Failure Treatment and Management | 2021-2025 | 131 | ES 4 | 98.44 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 261 | ES 9 | 98.03 |
| Medication Adherence and Compliance | 2021-2025 | 42 | ES 1 | 95.52 |
| Healthcare Systems and Technology | 2021-2025 | 35 | ES 1 | 93.74 |
| Pharmaceutical Economics and Policy | 2021-2025 | 89 | ES 1 | 93.83 |
| Diabetes Treatment and Management | 2021-2025 | 410 | ES 8 | 95.61 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 725 | ES 14 | 94.36 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 455 | ES 13 | 95.06 |
| Acute Myocardial Infarction Research | 2021-2025 | 495 | ES 14 | 94.20 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 379 | ES 17 | 92.76 |
| Cardiac Health and Mental Health | 2021-2025 | 363 | ES 9 | 90.42 |
| Telemedicine and Telehealth Implementation | 2021-2025 | 321 | ES 3 | 88.35 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 59 | ES 2 | 84.72 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 287 | ES 5 | 84.53 |
| Hormonal Regulation and Hypertension | 2021-2025 | 526 | ES 24 | 86.05 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 533 | ES 18 | 64.25 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 796 | ES 13 | 64.06 |
| Blood transfusion and management | 2021-2025 | 937 | ES 15 | 58.61 |
| Health and Medical Education | 2021-2025 | 479 | ES 50 | 56.17 |
| Pericarditis and Cardiac Tamponade | 2021-2025 | 682 | ES 27 | 54.37 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 619 | ES 39 | 49.02 |
| Quality and Safety in Healthcare | 2021-2025 | 938 | ES 19 | 24.40 |
